依达拉奉对重症急性脑梗塞患者超敏C-反应蛋白的影响及临床意义被引量：3

下载PDF

导出

摘要目的观察依达拉奉对重症急性脑梗塞患者血清超敏C-反应蛋白(hs-CRP)的影响,探讨其临床意义。方法随机将134例重型急性脑梗塞患者分为两组,两组常规治疗相同,在此基础上治疗组给予依达拉奉30mg加生理盐水100ml静脉滴注,每日2次;对照组给予吡拉西坦8.0g加生理盐水250ml静脉滴注,每日1次,疗程均为14天。分别在治疗前和治疗后第7、第14天检测血清hs-CRP水平,并进行欧洲卒中评分(ESS)。结果治疗组治疗后第7、第14天重症急性脑梗塞患者血清hs-CRP水平明显降低,ESS评分明显改善,与对照组比较差异有显著性(P<0.05或P<0.01)。结论依达拉奉能有效抑制重症急性脑梗塞的炎症反应,降低血清hs-CRP水平,改善神经功能。

作者杜福文林晖黄丽华杜福亮

机构地区广西防城港市第一人民医院神经内科

出处《右江民族医学院学报》 2008年第6期959-960,共2页 Journal of Youjiang Medical University for Nationalities

关键词脑梗塞/治疗依达拉奉超敏C-反应蛋白

分类号 R743.33 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献6

1谢良麒,王宪.C反应蛋白与动脉粥样硬化[J].生理科学进展,2004,35(2):113-118. 被引量：86
2高亮.C反应蛋白在急性脑梗死发病中作用机制的探讨[J].山西医药杂志,2004,33(6):475-477. 被引量：35
3朱树花,王翠兰.超敏C-反应蛋白在老年急性脑梗死患者中的表达[J].中国老年学杂志,2007,27(16):1620-1621. 被引量：11
4MuirWeir CJ, Alwan W. C - reaction protein and outcome after ischemic stroke [J]. Lancet, 1999,30(5):981.
5DiNapoli M, Papa F, Bocola V, et al. Prognostic influence of increased C - reactive protein and fibrinogen levels in ischemic stroke [J]. Stroke,2001,32(1) :133 - 138.
6Tohgi H, Konno S, Takahashi S, et al. Activate coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C- reactive protein levels [J]. Thromb Res,2000,100(5):373 - 379.

二级参考文献36

1脑卒中患者临床神经功能缺损程度评分标准（1995）[J].中华神经科杂志,1996,29(6):381-383. 被引量：15780
2[1]Jabs WJ, Logering BA, Gerke P, et al. Kidney as a second site of human C-reactive protein formation in vivo. Eur J immunology, 2003, 33 152～161.
3[2]Woo P, Korenberg JR, Whitehead AS, et al. Characterizaton of genomic and complementary DNA sequence of human C-reactive protein,and comparison with the complementary DNA sequence of serum amyloid P component. J Biol Chem,1989,260 13384～13388
4[3]Shrive AK, Gheetham GM,Holden D, et al. Three dimention structure of C-reactive protein. Nature Struc Biol,1996,3 346～354.
5[4]Angrawal A, Lee S, Carson M, et al. Site-directed mutagenesis of the phosphocholine-binding site of human C-reactive protein. J Immunol,1997,166 3998～4004.
6[5]Bharadwaj D,Stein MP,Volzer M, et al. The major receptor for C-reactive protein on leukorcyte is FcgRII .J Exp Med,1999,190 585～590
7[6]Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circulation Res, 2001,89 763～771.
8[7]Liuzzo G,Biasucci LM,Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med, 1994,331 417～424.
9[8]Biasucci LM,Liuzzo G,Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predicts recurrent instability.Circulation,1999,99 855～860.
10[9]Gaspardone A,Grea F,Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol,1998,82 515～518.